RAISING THE BAR BY LOWERING THE TARGET Integrating PCSK9 Inhibitors into Hypercholesterolemia Management
Format: Resource Center
Credits: 0.25 AMA PRA Category 1 Credit™ per module
This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.
During these quick-hitting activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9). Physicians can complete all 7 video modules for a total of 2.0 AMA PRA Category 1 Credits™.